Prolevi is an international start-up with a long-term aim to target metabolic disorders. Women’s health is largely underfunded, and Prolevi initially addresses one of the biggest challenges, hypothyroidism (80-90% females) which is an area with large unmet need as many patients do not respond to current therapy. The company is developing personalized therapy, by biomimicking the natural release cycles for the active thyroid hormone in non-respondents.
